Pharmicell Co., Ltd. (005690.KS)
KRW 8000.0
(0.63%)
KRW 8000.0
(0.63%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 14 Billion KRW | -6.3% |
| 2022 | 14.94 Billion KRW | -5.67% |
| 2021 | 15.84 Billion KRW | 50.25% |
| 2020 | 10.54 Billion KRW | -4.71% |
| 2019 | 11.06 Billion KRW | -4.12% |
| 2018 | 11.54 Billion KRW | -7.86% |
| 2017 | 12.52 Billion KRW | 3.69% |
| 2016 | 12.08 Billion KRW | 9.02% |
| 2015 | 11.08 Billion KRW | -9.64% |
| 2014 | 12.26 Billion KRW | -25.15% |
| 2013 | 16.38 Billion KRW | 6.68% |
| 2012 | 15.36 Billion KRW | 13.21% |
| 2011 | 13.56 Billion KRW | 24.28% |
| 2010 | 10.91 Billion KRW | 136.67% |
| 2009 | 4.61 Billion KRW | -14.93% |
| 2008 | 5.42 Billion KRW | -25.71% |
| 2007 | 7.29 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 4.27 Billion KRW | 15.55% |
| 2024 Q2 | 3.31 Billion KRW | -22.44% |
| 2023 Q4 | 3.7 Billion KRW | 22.42% |
| 2023 FY | 14 Billion KRW | -6.3% |
| 2023 Q1 | 3.57 Billion KRW | -26.46% |
| 2023 Q2 | 3.74 Billion KRW | 4.76% |
| 2023 Q3 | 3.02 Billion KRW | -19.34% |
| 2022 Q1 | 3.27 Billion KRW | -46.92% |
| 2022 Q2 | 3.71 Billion KRW | 13.51% |
| 2022 Q4 | 4.86 Billion KRW | 57.84% |
| 2022 Q3 | 3.08 Billion KRW | -17.11% |
| 2022 FY | 14.94 Billion KRW | -5.67% |
| 2021 Q1 | 4.15 Billion KRW | 60.92% |
| 2021 Q3 | 2.96 Billion KRW | 15.89% |
| 2021 Q4 | 6.17 Billion KRW | 108.48% |
| 2021 Q2 | 2.55 Billion KRW | -38.48% |
| 2021 FY | 15.84 Billion KRW | 50.25% |
| 2020 FY | 10.54 Billion KRW | -4.71% |
| 2020 Q3 | 2.71 Billion KRW | 8.18% |
| 2020 Q2 | 2.51 Billion KRW | -7.93% |
| 2020 Q4 | 2.58 Billion KRW | -5.09% |
| 2020 Q1 | 2.73 Billion KRW | -14.09% |
| 2019 Q4 | 3.17 Billion KRW | 22.49% |
| 2019 FY | 11.06 Billion KRW | -4.12% |
| 2019 Q1 | 2.57 Billion KRW | -8.26% |
| 2019 Q2 | 2.72 Billion KRW | 5.77% |
| 2019 Q3 | 2.59 Billion KRW | -4.66% |
| 2018 FY | 11.54 Billion KRW | -7.86% |
| 2018 Q3 | 2.93 Billion KRW | -2.07% |
| 2018 Q2 | 2.99 Billion KRW | 6.65% |
| 2018 Q1 | 2.8 Billion KRW | -30.45% |
| 2018 Q4 | 2.8 Billion KRW | -4.41% |
| 2017 FY | 12.52 Billion KRW | 3.69% |
| 2017 Q2 | 2.93 Billion KRW | 5.16% |
| 2017 Q4 | 4.03 Billion KRW | 46.01% |
| 2017 Q3 | 2.76 Billion KRW | -5.71% |
| 2017 Q1 | 2.78 Billion KRW | -19.37% |
| 2016 Q1 | 3.11 Billion KRW | -2.22% |
| 2016 Q3 | 2.54 Billion KRW | -14.18% |
| 2016 FY | 12.08 Billion KRW | 9.02% |
| 2016 Q2 | 2.96 Billion KRW | -5.03% |
| 2016 Q4 | 3.45 Billion KRW | 36.1% |
| 2015 Q2 | 2.57 Billion KRW | -2.29% |
| 2015 Q4 | 3.18 Billion KRW | 18.86% |
| 2015 FY | 11.08 Billion KRW | -9.64% |
| 2015 Q1 | 2.63 Billion KRW | -18.32% |
| 2015 Q3 | 2.68 Billion KRW | 4.23% |
| 2014 Q3 | 2.75 Billion KRW | -10.27% |
| 2014 FY | 12.26 Billion KRW | -25.15% |
| 2014 Q4 | 3.22 Billion KRW | 16.94% |
| 2014 Q2 | 3.07 Billion KRW | -3.8% |
| 2014 Q1 | 3.19 Billion KRW | -43.03% |
| 2013 Q2 | 4.2 Billion KRW | 7.51% |
| 2013 FY | 16.38 Billion KRW | 6.68% |
| 2013 Q4 | 5.6 Billion KRW | 107.2% |
| 2013 Q3 | 2.7 Billion KRW | -35.68% |
| 2013 Q1 | 3.91 Billion KRW | -17.61% |
| 2012 Q2 | 3.49 Billion KRW | -12.46% |
| 2012 Q1 | 3.99 Billion KRW | 0.0% |
| 2012 FY | 15.36 Billion KRW | 13.21% |
| 2012 Q4 | 4.75 Billion KRW | 61.95% |
| 2012 Q3 | 2.93 Billion KRW | -16.12% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | 13.56 Billion KRW | 24.28% |
| 2011 Q3 | 4.52 Billion KRW | 92.88% |
| 2011 Q1 | 2.29 Billion KRW | -41.87% |
| 2011 Q2 | 2.34 Billion KRW | 1.93% |
| 2010 Q2 | 2.52 Billion KRW | 17.0% |
| 2010 Q3 | 2.24 Billion KRW | -11.35% |
| 2010 Q4 | 3.95 Billion KRW | 76.48% |
| 2010 FY | 10.91 Billion KRW | 136.67% |
| 2010 Q1 | 2.16 Billion KRW | 438.49% |
| 2009 Q1 | 1.19 Billion KRW | 422.45% |
| 2009 Q2 | 1.07 Billion KRW | -10.47% |
| 2009 Q3 | 1.94 Billion KRW | 81.25% |
| 2009 Q4 | 401.35 Million KRW | -79.34% |
| 2009 FY | 4.61 Billion KRW | -14.93% |
| 2008 Q1 | 2.29 Billion KRW | -3.19% |
| 2008 Q4 | 229.15 Million KRW | -90.58% |
| 2008 Q3 | 2.43 Billion KRW | 106.31% |
| 2008 Q2 | 1.17 Billion KRW | -48.75% |
| 2008 FY | 5.42 Billion KRW | -25.71% |
| 2007 Q3 | 1.21 Billion KRW | -35.41% |
| 2007 Q1 | 1.81 Billion KRW | 0.0% |
| 2007 Q2 | 1.88 Billion KRW | 3.92% |
| 2007 FY | 7.29 Billion KRW | 0.0% |
| 2007 Q4 | 2.37 Billion KRW | 94.8% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| ORIENT BIO Inc. | 10.23 Billion KRW | -36.889% |
| Green Cross Holdings Corporation | 620.02 Billion KRW | 97.741% |
| Green Cross Holdings Corporation | 424.43 Billion KRW | 96.7% |
| Green Cross Corporation | 424.43 Billion KRW | 96.7% |
| GeneOne Life Science, Inc. | 40.6 Billion KRW | 65.514% |
| Celltrion, Inc. | 359.46 Billion KRW | 96.104% |
| Samsung Biologics Co.,Ltd. | 638.51 Billion KRW | 97.807% |
| SK bioscience Co.,Ltd. | 154.23 Billion KRW | 90.92% |
| SK Biopharmaceuticals Co., Ltd. | 358.33 Billion KRW | 96.092% |
| Prestige BioPharma Limited | 63.47 Billion KRW | 77.936% |